FluoroZen is a portable point-of-care device that can rapidly screen for mutations in the BRCA1 gene that are associated with breast cancer. The application analyses the colour spectrum in bodily material (a small amount of saliva or blood). The outcome arrives in just 20 minutes and can be easily read and interpreted by an app on a smartphone.
